Tong Tong

Tong Tong

Auto-generated profile, based on publicly available information

Tong Tong

Pharmacy, The First Affiliated Hospital of USTC, Hefei, Anhui, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2020 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
TTTong Tong
Tong Tong
YWYing-Qi Wu
Ying-Qi Wu
WNWei-Jian Ni
Wei-Jian Ni
ASAi-Zong Shen
Ai-Zong Shen
SLSheng Liu
Sheng Liu
Corona Virus Disease 2019 (COVID-19) broke out in 2019 and spread rapidly around the world. There is still no specific antiviral therapy to the current pandemic. In China, historical records show that Traditional Chinese Medicine (TCM) is effective in prevention and enhancing the resistance to pandemic with unique insights. To fight with COVID-19, National Health and Commission of PRC has recommended some TCM in the guideline, such as HuoxiangZhengqi, LianhuaQingwen ShufengJiedu and XueBijing, and actually displayed a remarkable effect in clinical treatment strategic for COVID-19. We review studies to provide an in-depth understanding into the effect of TCM, and also introduce the possible mechanism involved in COVID-19 treatment.

21 March 2024 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
TTTong Tong
Tong Tong
YJYihua Jin
Yihua Jin
MWMin Wang
Min Wang
FGFang-qi Gong
Fang-qi Gong

22 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TTTong Tong
Tong Tong
PLPeifang Li
Peifang Li
HDHaiwen Ding
Haiwen Ding
YHYing Huang
Ying Huang
SLSheng Liu
Sheng Liu
Objective: Xuebijing injection (XBJ) is a commonly used herbal medicine injection in China. However, the physical compatibility of XBJ with other intravenous drugs remains unclear. The purpose of this research is to evaluate physical compatibility of Xuebijing injection (XBJ) with 53 intravenous drugs (including 31 Chinese medicine injections and 22 chemicals) during simulated Y-site administration.Methods: Y-site administration was simulated in vitro by admixing 0.33 ml/ml XBJ with an equal volume of other diluted 53 intravenous drugs, respectively. Physical compatibility including visual inspection, Tyndall beam, particle limits, turbidity, pH, chromacity value, spectroscopic absorption of 550 nm and 420 nm (A550 nmand A420 nm) were observed and assessed at 0, 1, 2, and 4 h. Physical compatibility was defined as all solutions with no color changes, no gas evolution, particulate formation and no Tyndall beam within 4 hours, turbidity changes <0.5 nephelometric turbidity unit (NTU) compared to 0 h, particle limits allowed by the Chinese Pharmacopoeia (Ch.P) 2020 edition, pH changes <10% compared to 0, chromacity value changes <200 compared to 0 h, or photometrical changes of A420 nm<0.0400 or A550 nm<0.0100 compared to 0 h.Results: XBJ was physically incompatible with 27 of the 53 intravenous drugs tested, 26 were compatible with XBJ for 4 h.Conclusions: XBJ should not be simultaneously co-administered with 27 of the 53 intravenous drugs during simulated Y-site. If coadministration was inevitable, flushing tube with NS or D5W before and after infusion of XBJ was needed. Assessment included visual inspection, Tyndall beam, turbidity measurement, particle counts, pH measurement, chromacity value measurement and absorption of A550 nmwere proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.

3 March 2025 in European Journal of Hospital Pharmacy
Verified
Journal Article
Open access
PDF file
FCFangyuan Chen
Fangyuan Chen
HDHaiwen Ding
Haiwen Ding
SLSheng Liu
Sheng Liu
ZCZhaolin Chen
Zhaolin Chen
LTLiqin Tang
Liqin Tang
TTTong Tong
Tong Tong
Objective The primary objective of this study was to evaluate the physical compatibility of ceftazidime-avibactam with selected intravenous antimicrobials during simulated Y-site administration. Methods Ceftazidime-avibactam (25 mg/mL) was mixed with select intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) at an equal volume and evaluated using simulated Y-sites. Each admixture was evaluated immediately (0 hour) and after 1, 2, and 4 hours at room temperature (approximately 22°C) for visual characteristics, Tyndall beam, turbidity, pH, spectroscopic absorption of 550 nm and particle counts. If an admixture failed any one of these six assessments, it was considered incompatible. Results No evidence of incompatibility was observed between the combinations of ceftazidime-avibactam and the seven intravenous antimicrobials in simulated Y-site experiments. Conclusion Ceftazidime-avibactam was physically compatible with the selected intravenous antimicrobials (tigecycline, metronidazole, meropenem, imipenem and cilastatin, fosfomycin, aztreonam and vancomycin) in simulated Y-site administration.

1 January 2025 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
HDHaiwen Ding
Haiwen Ding
TTTong Tong
Tong Tong
JLJie Li
Jie Li
ZCZhaolin Chen
Zhaolin Chen
LTLiqin Tang
Liqin Tang
PLPeifang Li
Peifang Li
Objective: Ginkgo biloba extract (EGB), a traditional Chinese medicine extracted from the Ginkgophyta, was used to regulate various neurological disorders (NDs). Limited compatibility data exist on EGB after marketing with other drugs administered simultaneously through the Y‐site. This study aimed to determine the compatibility of EGB during simulated Y‐site administration with 35 continuous infusion drugs that are commonly administered in the neurological intensive care units ( NICU s). Methods: The compatibility of EGB with these drugs was determined using a well‐established experimental model to simulate Y‐site administration. EGB (0.35 mg/mL) was mixed in a volume ratio of 1:1 with the secondary drug solution to simulate Y‐site coadministration procedures in NICUs. All other drugs were prepared at maximum concentrations commonly administered in the clinical setting. Compatibility was assessed by visual inspection (observations of haziness, color change, or precipitate formation), the Tyndall effect, chromaticity, pH, turbidity, insoluble particles, and UV absorption at 0, 1, 2, and 4 h postmixing. Results: This study has identified 25 (71%) combinations that are compatible and 10 combinations that are incompatible within four hours. Visual changes occurred with EGB + acyclovir and EGB + ganciclovir. The turbidity of the mixed solution of EGB + calcium gluconate exceeds the specification. Binary combinations of EGB + aceglutamide, EGB + aescin sodium, EGB + amiodarone hydrochloride, EGB + fosfomycin, EGB + ganciclovir, EGB + meropenem, EGB + omeprazole, and EGB + vinpocetine had particles that grew over the limitation of the Chinese Pharmacopoeia specification. Both admixtures of EGB + acyclovir and EGB + amiodarone hydrochloride absorption at 420 nm and 550 nm exceeded the prescribed limits. Conclusion: It is strongly advised against combining EGB 0.35 mg/mL with acyclovir, aceglutamide, aescin sodium, amiodarone hydrochloride, calcium gluconate, fosfomycin sodium, ganciclovir, meropenem, or omeprazole, as well as vinpocetine. If coadministration is inevitable, a larger volume of saline (NS) or dextrose 5% in water (D5W) should be used to flush the port catheter before and after the EGB infusion to clean the lumen of the port catheter.